Engineered HCV E2 immunogens and related vaccine compositions
US11008368B2 · kind B2 · utility
0Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 24, 2020 |
| Grant date | May 18, 2021 |
| Priority date | — |
| Expiry date | Jul 24, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/24234
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel engineered HCV E2 polypeptide immunogens and related vaccine compositions that display the engineered E2 polypeptides. The invention also provides methods of using such immunogens and vaccine compositions in various therapeutic applications, e.g., for preventing or treating HCV infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.